PL3969009T3 - Beta-1,3'-galaktozylolaktoza do leczenia chorób związanych z funkcją bariery jelitowej - Google Patents

Beta-1,3'-galaktozylolaktoza do leczenia chorób związanych z funkcją bariery jelitowej

Info

Publication number
PL3969009T3
PL3969009T3 PL20724883.2T PL20724883T PL3969009T3 PL 3969009 T3 PL3969009 T3 PL 3969009T3 PL 20724883 T PL20724883 T PL 20724883T PL 3969009 T3 PL3969009 T3 PL 3969009T3
Authority
PL
Poland
Prior art keywords
galactosyllactose
beta
treatment
barrier function
gut barrier
Prior art date
Application number
PL20724883.2T
Other languages
English (en)
Inventor
Saskia BRABER
Belinda Potappel - Van 't Land
Selma Paulien WIERTSEMA
Johan Garssen
Bernd Stahl
Marko Mank
Original Assignee
N.V. Nutricia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by N.V. Nutricia filed Critical N.V. Nutricia
Publication of PL3969009T3 publication Critical patent/PL3969009T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/03—Organic compounds
    • A23L29/035—Organic compounds containing oxygen as heteroatom
    • A23L29/04—Fatty acids or derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/30—Foods or foodstuffs containing additives; Preparation or treatment thereof containing carbohydrate syrups; containing sugars; containing sugar alcohols, e.g. xylitol; containing starch hydrolysates, e.g. dextrin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pediatric Medicine (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL20724883.2T 2019-05-15 2020-05-15 Beta-1,3'-galaktozylolaktoza do leczenia chorób związanych z funkcją bariery jelitowej PL3969009T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19174750 2019-05-15
PCT/EP2020/063720 WO2020229690A1 (en) 2019-05-15 2020-05-15 Beta-1,3'-galactosyllactose for the treatment of gut barrier function diseases

Publications (1)

Publication Number Publication Date
PL3969009T3 true PL3969009T3 (pl) 2026-01-19

Family

ID=66624991

Family Applications (1)

Application Number Title Priority Date Filing Date
PL20724883.2T PL3969009T3 (pl) 2019-05-15 2020-05-15 Beta-1,3'-galaktozylolaktoza do leczenia chorób związanych z funkcją bariery jelitowej

Country Status (9)

Country Link
US (1) US12508273B2 (pl)
EP (1) EP3969009B1 (pl)
CN (1) CN113840611A (pl)
AU (1) AU2020275468B2 (pl)
BR (1) BR112021022447A2 (pl)
ES (1) ES3051932T3 (pl)
PH (1) PH12021552677A1 (pl)
PL (1) PL3969009T3 (pl)
WO (1) WO2020229690A1 (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12021551814A1 (en) * 2019-06-04 2022-03-21 Nutricia Nv NUTRITIONAL COMPOSITION COMPRISING 2’FUCOSYLLACTOSE AND 3’GALACTOSYLLACTOSE
PT3883393T (pt) * 2019-06-04 2022-12-07 Nutricia Nv Composição nutricional compreendendo 2'fucosilactose e butirato dietético
EP4333649B1 (en) * 2021-05-03 2025-04-23 N.V. Nutricia Galactooligosaccharides for improving immune response
EP4362708A1 (en) 2021-07-01 2024-05-08 N.V. Nutricia Nutritonal compositions for gut barrier function
GB2623336A (en) * 2022-10-12 2024-04-17 Clasado Res Services Limited Compositions and uses thereof
GB2623335A (en) * 2022-10-12 2024-04-17 Clasado Res Services Limited Compositions and uses thereof
WO2025233459A1 (en) 2024-05-08 2025-11-13 N.V. Nutricia Nutritional composition for preventing intestinal barrier disruption

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2723960B1 (fr) 1994-08-31 1996-10-11 Gervais Danone Co Cultures de streptococcus thermophilus a activite beta-galactosidase elevee, leur procede d'obtention, et leurs utilisations
FR2723963B1 (fr) 1994-08-31 1997-01-17 Gervais Danone Co Preparation de produits fermentes par streptococcus thermophilus, enrichis en galacto-oligosaccharides et en beta-galactosidase
ATE360682T1 (de) * 2003-06-30 2007-05-15 Clasado Inc Neue galactooligosaccharidzusammensetzung und herstellung davon
US8252769B2 (en) 2004-06-22 2012-08-28 N. V. Nutricia Intestinal barrier integrity
US8075934B2 (en) * 2008-10-24 2011-12-13 Mead Johnson Nutrition Company Nutritional composition with improved digestibility
GB0809921D0 (en) * 2008-05-30 2008-07-09 Clasado Inc Product and process therefor
GB0906983D0 (en) * 2009-04-23 2009-06-03 Clasado Inc Novel use
WO2010143940A1 (en) * 2009-06-12 2010-12-16 N.V. Nutricia Synergistic mixture of beta-galacto-oligosaccharides with beta-1,3 and beta-1,4/1,6 linkages
EP2404507A1 (en) * 2010-07-08 2012-01-11 Nestec S.A. Array of age-tailored nutritional formula with optimum fat content
WO2013016111A1 (en) * 2011-07-22 2013-01-31 Abbott Laboratories Galactooligosaccharides for preventing injury and/or promoting healing of the gastrointestinal tract
CN104023560A (zh) * 2011-08-29 2014-09-03 雅培制药有限公司 用于预防胃肠道损伤和/或促进胃肠道愈合的人乳寡糖
EP2928325A1 (en) * 2012-12-10 2015-10-14 N.V. Nutricia Nutritional composition with non digestible oligosaccharides
GB201305708D0 (en) * 2013-03-28 2013-05-15 Clasado Inc Novel use
JP2014210718A (ja) * 2013-04-18 2014-11-13 独立行政法人農業・食品産業技術総合研究機構 腸管バリア機能改善剤
WO2016013928A1 (en) 2014-07-24 2016-01-28 N.V. Nutricia Prevention or treatment of food allergy in infants and toddlers
US11642359B2 (en) * 2018-07-12 2023-05-09 N.V. Nutricia Nutritional composition for improving intestinal barrier integrity, preparation of the composition and method of treatment
PH12021551814A1 (en) * 2019-06-04 2022-03-21 Nutricia Nv NUTRITIONAL COMPOSITION COMPRISING 2’FUCOSYLLACTOSE AND 3’GALACTOSYLLACTOSE

Also Published As

Publication number Publication date
US20220218728A1 (en) 2022-07-14
EP3969009A1 (en) 2022-03-23
CN113840611A (zh) 2021-12-24
PH12021552677A1 (en) 2022-07-04
AU2020275468B2 (en) 2024-06-27
EP3969009B1 (en) 2025-08-20
ES3051932T3 (en) 2025-12-30
AU2020275468A2 (en) 2021-12-16
AU2020275468A1 (en) 2021-12-02
WO2020229690A1 (en) 2020-11-19
BR112021022447A2 (pt) 2021-12-28
US12508273B2 (en) 2025-12-30
EP3969009C0 (en) 2025-08-20

Similar Documents

Publication Publication Date Title
PL3969009T3 (pl) Beta-1,3'-galaktozylolaktoza do leczenia chorób związanych z funkcją bariery jelitowej
IL285782A (en) Compounds, compositions, and methods for treating disease
EP3954395A4 (en) Pharmaceutical composition for muscle disease treatment
IL280358B1 (en) Autotactic chimeric compound and compositions for preventing, ameliorating or treating diseases by degrading a target protein containing them
WO2018022668A3 (en) NEUROMODULATORY COMPOSITIONS AND ASSOCIATED METHODS OF TREATING CANCER
EP3675859A4 (en) COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF A DISEASE
IL284414A (en) Methods and preparations for the treatment of Fabry disease
EP4467195A3 (en) Therapeutic agents for neurodegenerative diseases
IL279144A (en) Tetrahydro-1H-pyrazino[2,1-azisoindolylquinoline compounds for the treatment of immune system disease
IL290177A (en) History of 4,2,1-oxadiazol-5-one for cancer therapy
ZA202108219B (en) Combination treatment of arthritic disease
PH12019550138A1 (en) Pharmaceutical combinations for treating cancer
SG11202108119VA (en) Improved endoscope disinfectant
IL286646A (en) Preparations, devices and methods for the treatment of Fabry disease
EP3970793A4 (en) MEANS OF PREVENTING, IMPROVING OR TREATMENT OF PERIODONTAL DISEASES
MX2020003427A (es) Agentes terapeuticos para enfermedades neurodegenerativas.
EP3820477A4 (en) COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES
IL291640A (en) Compounds of 1,8-naphthyridin-2-one for the treatment of autoimmune disease
GB201916279D0 (en) Tobacco treatment
KR102316727B9 (ko) 아토피성 질환 예방 또는 치료용 약학적 조성물
GB201908453D0 (en) Compounds for treating respiratory disease
MX2019004200A (es) Terapia de combinacion.
IL283609A (en) Treatment by oral administration of 6, 8-bis-benzylthio-octanoic acid
EP3950707A4 (en) COMPOSITION COMPRISING LRRD2 SLIT3 COUPLED TO ALBUMIN FOR THE PREVENTION OR TREATMENT OF A MUSCLE DISEASE
GB201911728D0 (en) Bacterial composistions for the treatment of disease